Christopher Logothetis

List of Publications by Year
in descending order

176	13,567	30070 54	23533 111
papers	citations	h-index	g-index

185	185	185	16225
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Integrative Clinical and Genomic Characterization of MTAP-deficient Metastatic Urothelial Cancer. European Urology Oncology, 2023, 6, 228-232.	5.4	11
2	Genetic factors associated with prostate cancer conversion from active surveillance to treatment. Human Genetics and Genomics Advances, 2022, 3, 100070.	1.7	10
3	Prostate tumor-induced stromal reprogramming generates Tenascin C that promotes prostate cancer metastasis through YAP/TAZ inhibition. Oncogene, 2022, 41, 757-769.	5.9	12
4	Prostate cancer risk stratification improvement across multiple ancestries with new polygenic hazard score. Prostate Cancer and Prostatic Diseases, 2022, 25, 755-761.	3.9	14
5	Third analysis of a randomized trial of finite abiraterone acetate (AA) plus LHRH agonist (LHRHa) versus LHRHa in biochemically recurrent, non-metastatic hormone-naÃ¯ve prostate cancer (M0HNPC).. Journal of Clinical Oncology, 2022, 40, 135-135.	1.6	0
6	Factors associated with improved outcomes in surgically resectable small cell urothelial cancer (SCUC).. Journal of Clinical Oncology, 2022, 40, 495-495.	1.6	0
7	What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021. European Urology, 2022, 82, 6-11.	1.9	4
8	MTAP deficiency creates an exploitable target for antifolate therapy in 9p21-loss cancers. Nature Communications, 2022, 13, 1797.	12.8	23
9	Mesenchymal and stem-like prostate cancer linked to therapy-induced lineage plasticity and metastasis. Cell Reports, 2022, 39, 110595.	6.4	25
10	Effects of metformin and statins on outcomes in men with castration-resistant metastatic prostate cancer: Secondary analysis of COU-AA-301 and COU-AA-302. European Journal of Cancer, 2022, 170, 296-304.	2.8	14
11	Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy. Nature, 2022, 606, 797-803.	27.8	54
12	DynAMo: A dynamic allocation modular sequential trial of approved and promising therapies in men with metastatic CRPC.. Journal of Clinical Oncology, 2022, 40, 5059-5059.	1.6	0
13	Retinoic Acid Receptor Activation Reduces Metastatic Prostate Cancer Bone Lesions by Blocking the Endothelial-to-Osteoblast Transition. Cancer Research, 2022, 82, 3158-3171.	0.9	9
14	A Phase 2 Trial of Abiraterone Followed by Randomization to Addition of Dasatinib or Sunitinib in Men With Metastatic Castration-Resistant Prostate Cancer. Clinical Genitourinary Cancer, 2021, 19, 22-31.e5.	1.9	8
15	Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction. Nature Genetics, 2021, 53, 65-75.	21.4	264
16	Additional SNPs improve risk stratification of a polygenic hazard score for prostate cancer. Prostate Cancer and Prostatic Diseases, 2021, 24, 532-541.	3.9	16
17	Polygenic hazard score is associated with prostate cancer in multi-ethnic populations. Nature Communications, 2021, 12, 1236.	12.8	40
18	Outcomes in men with metastatic castrate-resistant prostate cancer treated with early platinum-based chemotherapy following an unsatisfactory response to androgen receptor (AR) inhibition as part of the phase II dynamic allocation modular sequential (DynAMo) trial.. Journal of Clinical Oncology, 2021, 39, 83-83.	1.6	1

#	Article	IF	Citations
19	Large Extracellular Vesicle Characterization and Association with Circulating Tumor Cells in Metastatic Castrate Resistant Prostate Cancer. Cancers, 2021, 13, 1056.	3.7	21
20	Radium-223 Treatment Increases Immune Checkpoint Expression in Extracellular Vesicles from the Metastatic Prostate Cancer Bone Microenvironment. Clinical Cancer Research, 2021, 27, 3253-3264.	7.0	26
21	Multiple pathways coordinating reprogramming of endothelial cells into osteoblasts by BMP4. IScience, 2021, 24, 102388.	4.1	12
22	Statins reduce castration-induced bone marrow adiposity and prostate cancer progression in bone. Oncogene, 2021, 40, 4592-4603.	5.9	10
23	Factors Associated with Time to Conversion from Active Surveillance to Treatment for Prostate Cancer in a Multi-Institutional Cohort. Journal of Urology, 2021, 206, 1147-1156.	0.4	14
24	Evaluation of Technology-Enabled Monitoring of Patient-Reported Outcomes to Detect and Treat Toxic Effects Linked to Immune Checkpoint Inhibitors. JAMA Network Open, 2021, 4, e2122998.	5.9	13
25	Reply by Authors. Journal of Urology, 2021, 206, 1156.	0.4	0
26	P4HA2-induced prolyl hydroxylation suppresses YAP1-mediated prostate cancer cell migration, invasion, and metastasis. Oncogene, 2021, 40, 6049-6056.	5.9	19
27	Prostate cancer castrate resistant progression usage of non-canonical androgen receptor signaling and ketone body fuel. Oncogene, 2021, 40, 6284-6298.	5.9	13
28	The protein arginine methyltransferases (PRMTs) PRMT1 and CARM1 as candidate epigenetic drivers in prostate cancer progression. Medicine (United States), 2021, 100, e27094.	1.0	11
29	Measuring the Metabolic Evolution of Glioblastoma throughout Tumor Development, Regression, and Recurrence with Hyperpolarized Magnetic Resonance. Cells, 2021, 10, 2621.	4.1	4
30	Abiraterone acetate plus prednisone in non-metastatic biochemically recurrent castration-naÃ¯ve prostate cancer. European Journal of Cancer, 2021, 157, 259-267.	2.8	4
31	Combined CTLA-4 and PD-L1 blockade in patients with chemotherapy-naÃ¯ve metastatic castration-resistant prostate cancer is associated with increased myeloid and neutrophil immune subsets in the bone microenvironment. , 2021, 9, e002919.		30
32	Genome-wide DNA methylation profiling of leukocytes identifies CpG methylation signatures of aggressive prostate cancer. American Journal of Cancer Research, 2021, 11, 968-978.	1.4	1
33	Association of High-Intensity Exercise with Renal Medullary Carcinoma in Individuals with Sickle Cell Trait: Clinical Observations and Experimental Animal Studies. Cancers, 2021, 13, 6022.	3.7	14
34	Mitochondrial DNA copy number in peripheral blood leukocytes is associated with biochemical recurrence in prostate cancer patients in African Americans. Carcinogenesis, 2020, 41, 267-273.	2.8	11
35	Determining Clinically Based Factors Associated With Reclassification in the Pre-MRI Era using a Large Prospective Active Surveillance Cohort. Urology, 2020, 138, 91-97.	1.0	6
36	Epigenetics and prostate cancer: defining the timing of DNA methyltransferase deregulation during prostate cancer progression. Pathology, 2020, 52, 218-227.	0.6	24

#	Article	IF	Citations
37	Contemporary prostate cancer treatment choices in multidisciplinary clinics referenced to national trends. Cancer, 2020, 126, 506-514.	4.1	21
38	Urothelial-to-Neural Plasticity Drives Progression to Small Cell Bladder Cancer. IScience, 2020, 23, 101201.	4.1	18
39	The CHEK2 Variant C.349A>G Is Associated with Prostate Cancer Risk and Carriers Share a Common Ancestor. Cancers, 2020, 12, 3254.	3.7	16
40	Single-Cell Circulating Tumor Cell Analysis Reveals Genomic Instability as a Distinctive Feature of Aggressive Prostate Cancer. Clinical Cancer Research, 2020, 26, 4143-4153.	7.0	50
41	Comparative Survival of Asian and White Metastatic Castration-Resistant Prostate Cancer Men Treated With Docetaxel. JNCI Cancer Spectrum, 2020, 4, pkaa003.	2.9	1
42	Assessment of Luminal and Basal Phenotypes in Bladder Cancer. Scientific Reports, 2020, 10, 9743.	3.3	83
43	Genetic variants in epithelialâ€“mesenchymal transition genes as predictors of clinical outcomes in localized prostate cancer. Carcinogenesis, 2020, 41, 1057-1064.	2.8	0
44	Neoantigen responses, immune correlates, and favorable outcomes after ipilimumab treatment of patients with prostate cancer. Science Translational Medicine, 2020, 12, .	12.4	108
45	Decoding the evolutionary response to prostate cancer therapy by plasma genome sequencing. Genome Biology, 2020, 21, 162.	8.8	14
46	The MD Anderson Prostate Cancer Patient-derived Xenograft Series (MDA PCa PDX) Captures the Molecular Landscape of Prostate Cancer and Facilitates Marker-driven Therapy Development. Clinical Cancer Research, 2020, 26, 4933-4946.	7.0	53
47	A Phase II Study of Cabozantinib and Androgen Ablation in Patients with Hormone-NaÃ¯ve Metastatic Prostate Cancer. Clinical Cancer Research, 2020, 26, 990-999.	7.0	11
48	Leukocyte telomere length is associated with aggressive prostate cancer in localized prostate cancer patients. EBioMedicine, 2020, 52, 102616.	6.1	14
49	Resistance to MET/VEGFR2 Inhibition by Cabozantinib Is Mediated by YAP/TBX5-Dependent Induction of FGFR1 in Castration-Resistant Prostate Cancer. Cancers, 2020, 12, 244.	3.7	21
50	A candidate androgen signalling signature predictive of response to abiraterone acetate in men with metastatic castration-resistant prostate cancer. European Journal of Cancer, 2020, 127, 67-75.	2.8	6
51	Neoadjuvant apalutamide (APA) plus leuprolide (LHRHa) with or without abiraterone (AA) in localized high-risk prostate cancer (LHRPC).. Journal of Clinical Oncology, 2020, 38, 5504-5504.	1.6	10
52	Fibroblast growth factors signaling in bone metastasis. Endocrine-Related Cancer, 2020, 27, R255-R265.	3.1	19
53	Analysis of chemotherapy-related modulation of the immune microenvironment in muscle invasive bladder cancer.. Journal of Clinical Oncology, 2020, 38, 5049-5049.	1.6	0
54	Androgen Receptor Signaling in Castration-Resistant Prostate Cancer Alters Hyperpolarized Pyruvate to Lactate Conversion and Lactate Levels In Vivo. Molecular Imaging and Biology, 2019, 21, 86-94.	2.6	20

#	Article	IF	Citations
55	Prostate Cancer: Quo Vadis?. European Urology, 2019, 76, 709-711.	1.9	3
56	Radiotherapy for metastatic prostate cancer. Lancet, The, 2019, 394, 829-830.	13.7	1
57	Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1â€“2 trial. Lancet Oncology, The, 2019, 20, 1432-1443.	10.7	115
58	Clinical and Biological Characterisation of Localised High-risk Prostate Cancer: Results of a Randomised Preoperative Study of a Luteinising Hormone-releasing Hormone Agonist with or Without Abiraterone Acetate plus Prednisone. European Urology, 2019, 76, 418-424.	1.9	43
59	Assessing Therapeutic Efficacy in Real-time by Hyperpolarized Magnetic Resonance Metabolic Imaging. Cells, 2019, 8, 340.	4.1	20
60	Oncogenic and osteolytic functions of histone demethylase NO66 in castration-resistant prostate cancer. Oncogene, 2019, 38, 5038-5049.	5.9	14
61	Whole-Organ Genomic Characterization of Mucosal Field Effects Initiating Bladder Carcinogenesis. Cell Reports, 2019, 26, 2241-2256.e4.	6.4	31
62	Radium 223-Mediated Zonal Cytotoxicity of Prostate Cancer in Bone. Journal of the National Cancer Institute, 2019, 111, 1042-1050.	6.3	20
63	Genetic associations of T cell cancer immune response with tumor aggressiveness in localized prostate cancer patients and disease reclassification in an active surveillance cohort. OncoImmunology, 2019, 8, e1483303.	4.6	7
64	Systematic Review of Systemic Therapies and Therapeutic Combinations with Local Treatments for High-risk Localized Prostate Cancer. European Urology, 2019, 75, 44-60.	1.9	48
65	A phase II trial to evaluate pemetrexed clinical responses in relation to tumor methylthioadenosine phosphorylase (MTAP) gene status in patients with previously treated metastatic urothelial carcinoma.. Journal of Clinical Oncology, 2019, 37, 385-385.	1.6	3
66	Role of Androgen Receptor Variants in Prostate Cancer: Report from the 2017 Mission Androgen Receptor Variants Meeting. European Urology, 2018, 73, 715-723.	1.9	105
67	Multiplex protein detection on circulating tumor cells from liquid biopsies using imaging mass cytometry. Convergent Science Physical Oncology, 2018, 4, 015002.	2.6	60
68	ER stress in prostate cancer: A therapeutically exploitable vulnerability?. Science Translational Medicine, 2018, 10, .	12.4	9
69	Targeting the MYCNâ€“PARPâ€“DNA Damage Response Pathway in Neuroendocrine Prostate Cancer. Clinical Cancer Research, 2018, 24, 696-707.	7.0	80
70	Intravital microscopy of osteolytic progression and therapy response of cancer lesions in the bone. Science Translational Medicine, 2018, 10, .	12.4	42
71	Function of Tumor Suppressors in Resistance to Antiandrogen Therapy and Luminal Epithelial Plasticity of Aggressive Variant Neuroendocrine Prostate Cancers. Frontiers in Oncology, 2018, 8, 69.	2.8	9
72	Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. Nature Genetics, 2018, 50, 928-936.	21.4	652

#	Article	IF	Citations
73	Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants. Nature Communications, 2018, 9, 2256.	12.8	88
74	Low serum testosterone is associated with tumor aggressiveness and poor prognosis in prostate cancer. Oncology Letters, 2017, 13, 1949-1957.	1.8	22
75	Endothelial-to-Osteoblast Conversion Generates Osteoblastic Metastasis of Prostate Cancer. Developmental Cell, 2017, 41, 467-480.e3.	7.0	75
76	Androgen receptor inhibitorâ€“induced â€œBRCAnessâ€•and PARP inhibition are synthetically lethal for castration-resistant prostate cancer. Science Signaling, 2017, 10, .	3.6	200
77	VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer. Nature Medicine, 2017, 23, 551-555.	30.7	467
78	H3 ubiquitination by NEDD4 regulates H3 acetylation and tumorigenesis. Nature Communications, 2017, 8, 14799.	12.8	34
79	Paired High-Content Analysis of Prostate Cancer Cells in Bone Marrow and Blood Characterizes Increased Androgen Receptor Expression in Tumor Cell Clusters. Clinical Cancer Research, 2017, 23, 1722-1732.	7.0	26
80	Clinical predictors of survival in patients with castration-resistant prostate cancer receiving sipuleucel-T cellular immunotherapy. Cancer Chemotherapy and Pharmacology, 2017, 80, 583-589.	2.3	6
81	Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer. Journal of Clinical Oncology, 2017, 35, 40-47.	1.6	577
82	Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 11919-11924.	7.1	197
83	Intratumoral heterogeneity: Role of differentiation in a potentially lethal phenotype of testicular cancer. Cancer, 2016, 122, 1836-1843.	4.1	39
84	Genetic variants of the Wnt signaling pathway as predictors of aggressive disease and reclassification in men with early stage prostate cancer on active surveillance. Carcinogenesis, 2016, 37, 965-971.	2.8	4
85	CXCL1 mediates obesity-associated adipose stromal cell trafficking and function in the tumour microenvironment. Nature Communications, 2016, 7, 11674.	12.8	118
86	The combination of serum insulin, osteopontin, and hepatocyte growth factor predicts time to castration-resistant progression in androgen dependent metastatic prostate cancer- an exploratory study. BMC Cancer, 2016, 16, 721.	2.6	12
87	Targeting of CYP17A1 Lyase by VT-464 Inhibits Adrenal and Intratumoral Androgen Biosynthesis and Tumor Growth of Castration Resistant Prostate Cancer. Scientific Reports, 2016, 6, 35354.	3.3	33
88	Disease reclassification risk with stringent criteria and frequent monitoring in men with favourableâ€risk prostate cancer undergoing active surveillance. BJU International, 2016, 118, 68-76.	2.5	27
89	Tissue Effects in a Randomized Controlled Trial of Short-term Finasteride in Early Prostate Cancer. EBioMedicine, 2016, 7, 85-93.	6.1	6
90	Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. Journal of Clinical Oncology, 2016, 34, 1402-1418.	1.6	1,089

#	Article	IF	Citations
91	Targeting YAP-Dependent MDSC Infiltration Impairs Tumor Progression. Cancer Discovery, 2016, 6, 80-95.	9.4	404
92	Combined Tumor Suppressor Defects Characterize Clinically Defined Aggressive Variant Prostate Cancers. Clinical Cancer Research, 2016, 22, 1520-1530.	7.0	206
93	Integrating Murine and Clinical Trials with Cabozantinib to Understand Roles of MET and VEGFR2 as Targets for Growth Inhibition of Prostate Cancer. Clinical Cancer Research, 2016, 22, 107-121.	7.0	44
94	Caveolin-1 regulates hormone resistance through lipid synthesis, creating novel therapeutic opportunities for castration-resistant prostate cancer. Oncotarget, 2016, 7, 46321-46334.	1.8	22
95	Identification of Bone-Derived Factors Conferring De Novo Therapeutic Resistance in Metastatic Prostate Cancer. Cancer Research, 2015, 75, 4949-4959.	0.9	43
96	Radiographic Progression-Free Survival As a Response Biomarker in Metastatic Castration-Resistant Prostate Cancer: COU-AA-302 Results. Journal of Clinical Oncology, 2015, 33, 1356-1363.	1.6	120
97	PRUNE2 is a human prostate cancer suppressor regulated by the intronic long noncoding RNA PCA3. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 8403-8408.	7.1	226
98	Selection and identification of ligand peptides targeting a model of castrate-resistant osteogenic prostate cancer and their receptors. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 3776-3781.	7.1	53
99	Secretome Analysis of an Osteogenic Prostate Tumor Identifies Complex Signaling Networks Mediating Cross-talk of Cancer and Stromal Cells Within the Tumor Microenvironment. Molecular and Cellular Proteomics, 2015, 14, 471-483.	3.8	47
100	Molecular Characterization of Enzalutamide-treated Bone Metastatic Castration-resistant Prostate Cancer. European Urology, 2015, 67, 53-60.	1.9	205
101	Mitochondrial DNA copy number in peripheral blood leukocytes and the aggressiveness of localized prostate cancer. Oncotarget, 2015, 6, 41988-41996.	1.8	26
102	Impact of a Clinical Trial Initiative on Clinical Trial Enrollment in a Multidisciplinary Prostate Cancer Clinic. Journal of the National Comprehensive Cancer Network: JNCCN, 2014, 12, 993-998.	4.9	4
103	Aggressive Variants of Castration-Resistant Prostate Cancer. Clinical Cancer Research, 2014, 20, 2846-2850.	7.0	339
104	Cabozantinib in Chemotherapy-Pretreated Metastatic Castration-Resistant Prostate Cancer: Results of a Phase II Nonrandomized Expansion Study. Journal of Clinical Oncology, 2014, 32, 3391-3399.	1.6	110
105	Prostate cancer cellâ€“stromal cell crosstalk via FGFR1 mediates antitumor activity of dovitinib in bone metastases. Science Translational Medicine, 2014, 6, 252ra122.	12.4	86
106	Posttranslational regulation of Akt in human cancer. Cell and Bioscience, 2014, 4, 59.	4.8	111
107	The Prostate Cancer Susceptibility Variant rs2735839 Near KLK3 Gene Is Associated with Aggressive Prostate Cancer and Can Stratify Gleason Score 7 Patients. Clinical Cancer Research, 2014, 20, 5133-5139.	7.0	31
108	Intense Androgen-Deprivation Therapy With Abiraterone Acetate Plus Leuprolide Acetate in Patients With Localized High-Risk Prostate Cancer: Results of a Randomized Phase II Neoadjuvant Study. Journal of Clinical Oncology, 2014, 32, 3705-3715.	1.6	220

#	Article	IF	Citations
109	Prostate cancer bone metastases: not so systemic after all. Lancet Oncology, The, 2014, 15, 675-676.	10.7	2
110	Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncology, The, 2014, 15, 700-712.	10.7	1,280
111	Results of subset analyses on overall survival (OS) from study CA184-043: Ipilimumab (Ipi) versus placebo (Pbo) in post-docetaxel metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2014, 32, 2-2.	1.6	11
112	Characterization of immune-related adverse events (irAEs) in a phase 3 trial of ipilimumab (Ipi) versus placebo (Pbo) in post-docetaxel mCRPC.. Journal of Clinical Oncology, 2014, 32, 52-52.	1.6	1
113	Integrated Hedgehog signaling is induced following castration in human and murine prostate cancers. Prostate, 2013, 73, 153-161.	2.3	17
114	Targeting Constitutively Activated Î²1 Integrins Inhibits Prostate Cancer Metastasis. Molecular Cancer Research, 2013, 11, 405-417.	3.4	83
115	Molecular Classification of Prostate Cancer Progression: Foundation for Marker-Driven Treatment of Prostate Cancer. Cancer Discovery, 2013, 3, 849-861.	9.4	120
116	Re: Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing. European Urology, 2013, 64, 170.	1.9	6
117	Treatment of Castrate-Resistant Prostate Cancer. Journal of Urology, 2013, 190, 439-440.	0.4	1
118	Modified Logistic Regression Models Using Gene Coexpression and Clinical Features to Predict Prostate Cancer Progression. Computational and Mathematical Methods in Medicine, 2013, 2013, 1-7.	1.3	1
119	Overall survival (OS) and safety of dasatinib/docetaxel versus docetaxel in patients with metastatic castration-resistant prostate cancer (mCRPC): Results from the randomized phase III READY trial.. Journal of Clinical Oncology, 2013, 31, LBA8-LBA8.	1.6	30
120	Treatment of prostate cancer metastases: more than semantics. Lancet, The, 2012, 379, 4-6.	13.7	9
121	Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial. Lancet Oncology, The, 2012, 13, 1210-1217.	10.7	254
122	Aberrant expression of katanin p60 in prostate cancer bone metastasis. Prostate, 2012, 72, 291-300.	2.3	24
123	WHEN â€˜DUELING TECHNOLOGIESâ€™ ARE MISTAKEN FOR PROGRESS. BJU International, 2011, 107, 1699-1700	2.5	0
124	Neuroendocrine prostate cancer xenografts with largeâ€cell and smallâ€cell features derived from a single patient's tumor: Morphological, immunohistochemical, and gene expression profiles. Prostate, 2011, 71, 846-856.	2.3	68
125	Re: Final results of sequential doxorubicin plus gemcitabine and ifosfamide, paclitaxel, and cisplatin chemotherapy in patients with metastatic or locally advanced transitional cell carcinoma of the urothelium. European Urology, 2010, 57, 728-729.	1.9	1
126	Cadherin-11 Increases Migration and Invasion of Prostate Cancer Cells and Enhances their Interaction with Osteoblasts. Cancer Research, 2010, 70, 4580-4589.	0.9	113

#	Article	IF	Citations
127	Understanding the Biology of Bone Metastases: Key to the Effective Treatment of Prostate Cancer. Clinical Cancer Research, 2008, 14, 1599-1602.	7.0	43
128	High-Grade Prostate Cancer and the Prostate Cancer Prevention Trial. Cancer Prevention Research, 2008, 1, 151-152.	1.5	17
129	Cadherin-11 Promotes the Metastasis of Prostate Cancer Cells to Bone. Molecular Cancer Research, 2008, 6, 1259-1267.	3.4	162
130	Strategy for the Application of Therapy in Prostate Cancer. Advances in Experimental Medicine and Biology, 2008, 617, 193-199.	1.6	2
131	Androgen receptorâ€“negative human prostate cancer cells induce osteogenesis in mice through FGF9-mediated mechanisms. Journal of Clinical Investigation, 2008, 118, 2697-710.	8.2	153
132	Osteoblasts in prostate cancer metastasis to bone. Nature Reviews Cancer, 2005, 5, 21-28.	28.4	499
133	The case for a biologically based classification of prostate cancer. Seminars in Oncology, 2003, 30, 562-566.	2.2	2
134	Targeting prostate cancer bone metastases. Cancer, 2003, 97, 785-788.	4.1	12
135	Foundation for the integration of biologically based therapy in the management of prostate cancer. Prostate, 2003, 57, 32-38.	2.3	1
136	Docetaxel in the management of advanced or metastatic urothelial tract cancer. Oncology, 2002, 16, 107-11.	0.5	0
137	Docetaxel in the integrated management of prostate cancer. Current applications and future promise. Oncology, 2002, 16, 63-72.	0.5	8
138	Integrated Therapy for Locally Advanced Bladder Cancer: Final Report of a Randomized Trial of Cystectomy Plus Adjuvant M-VAC Versus Cystectomy With Both Preoperative and Postoperative M-VAC. Journal of Clinical Oncology, 2001, 19, 4005-4013.	1.6	284
139	Gemcitabine modulation of alkylator therapy. Cancer, 2001, 92, 194-199.	4.1	13
140	Germ cell tumors in patients infected by the human immunodeficiency virus. Cancer, 2001, 92, 1460-1467.	4.1	18
141	Molecular determinants of cell death induction following adenovirus-mediated gene transfer of wild-type p53 in prostate cancer cells. International Journal of Cancer, 2001, 91, 159-166.	5.1	2
142	A Phase II trial of bryostatin-1 for patients with metastatic renal cell carcinoma. Cancer, 2000, 89, 615-618.	4.1	44
143	Superimposed histologic and genetic mapping of chromosome 9 in progression of human urinary bladder neoplasia: implications for a genetic model of multistep urothelial carcinogenesis and early detection of urinary bladder cancer. Oncogene, 1999, 18, 1185-1196.	5.9	131
144	Brain metastasis from prostate carcinoma. Cancer, 1999, 86, 2301-2311.	4.1	96

#	Article	IF	Citations
145	Model systems of prostate cancer: uses and limitations. Cancer and Metastasis Reviews, 1998, 17, 361-371.	5.9	83
146	Molecular regulation of cell death and therapeutic strategies for cell death induction in prostate carcinoma. Cancer and Metastasis Reviews, 1998, 17, 345-351.	5.9	18
147	Prostate carcinoma cell death resulting from inhibition of proteasome activity is independent of functional Bcl-2 and p53. Oncogene, 1998, 17, 2889-2899.	5.9	117
148	Superimposed histologic and genetic mapping of chromosome 17 alterations in human urinary bladder neoplasia. Oncogene, 1997, 14, 2059-2070.	5.9	49
149	New approaches in the treatment of metastatic transitional-cell cancer of the bladder. World Journal of Urology, 1997, 15, 139-143.	2.2	8
150	Phase II trial of 5-fluorouracil, interferon-? and continuous infusion interleukin-2 for patients with metastatic renal cell carcinoma. Cancer, 1997, 80, 2128-2132.	4.1	62
151	Characterization of Patients with Androgen-Independent Prostatic Carcinoma Whose Serum Prostate Specific Antigen Decreased Following Flutamide Withdrawal. Journal of Urology, 1996, 155, 620-623.	0.4	50
152	Workgroup 3: Current prognostic factors and their relevance to staging. , 1996, 78, 369-371.		11
153	Growth-Inhibitory Effects of Serotonin Uptake Inhibitors on Human Prostate Carcinoma Cell Lines. Journal of Urology, 1995, 154, 247-250.	0.4	85
154	Surgery Following Response to Interfergn-Î±-Baseb Therapy for Residual Renal Cell Carcinoma. Journal of Urology, 1993, 149, 19-21.	0.4	89
155	Differential Effects of Peptide Hormones Bombesin, Vasoactive Intestinal Polypeptide and Somatostatin Analog RC-160 on the Invasive Capacity of Human Prostatic Carcinoma Cells. Journal of Urology, 1993, 149, 1209-1213.	0.4	140
156	Altered Expression of Retinoblastoma Protein and Known Prognostic Variables in Locally Advanced Bladder Cancer. Journal of the National Cancer Institute, 1992, 84, 1256-1261.	6.3	246
157	Dose Intensity in Germ Cell Tumors: Lessons Learned?. Journal of the National Cancer Institute, 1992, 84, 1686-1687.	6.3	2
158	Chemotherapy for Small Cell Carcinoma of Prostatic Origin. Journal of Urology, 1992, 147, 935-937.	0.4	148
159	Human prostate cancer model: Roles of growth factors and extracellular matrices. Journal of Cellular Biochemistry, 1992, 50, 99-105.	2.6	89
160	The inhibition of the paracrine progression of prostate cancer as an approach to early therapy of prostatic carcinoma. Journal of Cellular Biochemistry, 1992, 50, 128-134.	2.6	18
161	Chemotherapy resistant transitional cell carcinoma as a target for chemoprevention. Journal of Cellular Biochemistry, 1992, 50, 128-131.	2.6	1
162	Hyperthyroidism in men with germ cell tumors and high levels of betaâ€human chorionic gonadotropin. Cancer, 1992, 69, 1286-1290.	4.1	53

#	Article	IF	Citations
163	The case for relevant staging of germ cell tumors. Cancer, 1990, 65, 709-717.	4.1	8
164	Cisplatin, Cyclophosphamide and Doxorubicin Chemotherapy for Unresectable Urothelial Tumors: The M. D. Anderson Experience. Journal of Urology, 1989, 141, 33-37.	0.4	101
165	Spermatocytic seminoma with associated sarcoma of the testis. Cancer, 1988, 61, 409-414.	4.1	82
166	Clinical stage i nonseminomatous and mixed germ cell tumors of the testis. A clinicopathologic study of 93 patients on a surveillance protocol after orchiectomy alone. Cancer, 1988, 62, 1202-1206.	4.1	102
167	The Correlation of Vinblastine Pharmacokinetics to Toxicity in Testicular Cancer Patients. Journal of Clinical Pharmacology, 1988, 28, 714-718.	2.0	13
168	Cyclophosphamide and Sequential Cisplatin for Advanced Seminoma: Long-Term Followup in 52 Patients. Journal of Urology, 1987, 138, 789-794.	0.4	50
169	Small cell carcinoma of the prostate part I a clinicopathologic study of 20 cases. Cancer, 1987, 59, 1803-1809.	4.1	269
170	Carcinoembryonic Antigen and Beta-Human Chorionic Gonadotropin as Serum Markers for Advanced Urothelial Malignancies. Journal of Urology, 1986, 136, 403-407.	0.4	54
171	Orchiectomy in Advanced Germ Cell Cancer Following Intensive Chemotherapy: A Comparison of Systemic to Testicular Response. Journal of Urology, 1986, 136, 1221-1223.	0.4	47
172	Primary Chemotherapy Followed by a Selective Retro Peritoneal Lymphadenectomy in the Management of Clinical Stage II Testicular Carcinoma: A Preliminary Report. Journal of Urology, 1985, 134, 1127-1130.	0.4	31
173	Cyclophosphamide, Doxorubicin and Cisplatin Chemotherapy for Patients with Locally Advanced Urothelial Tumors with or without Nodal Metastases. Journal of Urology, 1985, 134, 460-464.	0.4	88
174	The management of brain metastases in germ cell tumors. Cancer, 1982, 49, 12-18.	4.1	134
175	Clinical Challenges for Treatment and a Cure. , 0, , 155-167.		0
176	Brain metastasis from prostate carcinoma. , 0, .		1